NMLSF Stock Chart & Stats
$0.06
-$0.01(-18.16%)
At close: 4:00 PM EDT
$0.06
-$0.01(-18.16%)
Day’s Range― - ―
52-Week Range$0.01 - $0.12
Previous CloseN/A
Volume1.02K
Average Volume (3M)455.00
Market Cap
$3.35M
Enterprise Value$4.75
Total Cash (Recent Filing)$762.36K
Total Debt (Recent Filing)$348.35K
Price to Earnings (P/E)―
Beta3.68
Next Earnings
Dec 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding62,506,542
10 Day Avg. Volume45
30 Day Avg. Volume455
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)3.29
Price to Sales (P/S)0.00
P/FCF Ratio-5.91
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet StabilizationPositive equity in 2025 and relatively low debt provide a stronger financial base than the prior two years. This can improve access to capital and preserve flexibility for development, although the history of volatility means the improvement must still be sustained.
Improving Cash BurnCash outflows improved materially from the 2021–2022 troughs, indicating some progress in controlling the rate of funding consumption. Even with 2025 cash flow still negative, a lower burn rate could extend financing runway if the trend continues.
Prior Positive Net IncomeNet income was positive in 2024, showing that the company can produce an accounting profit in at least one reported period. However, persistent operating losses and the pack’s note that non-operating or one-time drivers likely explain it limit its value as evidence of durable profitability.
Bears Say
No Recurring RevenueThe absence of reported revenue across five years indicates that commercial traction and recurring demand have not yet been established. Without a dependable top line, funding operations, validating the business model, and supporting future investment remain structurally difficult.
Persistent Operating LossesRecurring operating losses show that the core business has not reached profitability and is not yet converting activity into sustainable earnings. This weak earnings foundation can constrain reinvestment, increase dependence on financing, and make any isolated positive result less meaningful.
Ongoing Cash BurnContinued negative operating and free cash flow means the company is not self-funding its operations and remains reliant on external capital. That dependence can reduce strategic flexibility and expose the business to financing pressure while revenue and profitability remain unproven.
Restart Life Sciences News
NMLSF FAQ
What was Restart Life Sciences’s price range in the past 12 months?
Restart Life Sciences lowest stock price was $0.01 and its highest was $0.12 in the past 12 months.
What is Restart Life Sciences’s market cap?
Restart Life Sciences’s market cap is $3.35M.
When is Restart Life Sciences’s upcoming earnings report date?
Restart Life Sciences’s upcoming earnings report date is Dec 02, 2026 which is in 74 days.
How were Restart Life Sciences’s earnings last quarter?
Restart Life Sciences released its earnings results on Aug 27, 2026. The company reported -$0.012 earnings per share for the quarter.
Is Restart Life Sciences overvalued?
According to Wall Street analysts Restart Life Sciences’s price is currently Overvalued.
Does Restart Life Sciences pay dividends?
Restart Life Sciences does not currently pay dividends.
What is Restart Life Sciences’s EPS estimate?
Restart Life Sciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Restart Life Sciences have?
Restart Life Sciences has 62,506,542 shares outstanding.
What happened to Restart Life Sciences’s price movement after its last earnings report?
Restart Life Sciences reported an EPS of -$0.012 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Restart Life Sciences?
Currently, no hedge funds are holding shares in NMLSF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Restart Life Sciences
Operating internationally through its various subsidiaries, Restart Life Sciences Corp. functions as a biotechnology firm. Its core endeavors include the creation of natural therapeutic remedies tailored for individuals with autism spectrum disorder, the development of health-promoting foods designed for comprehensive mind and body wellness, and the execution of a psilocybin clinical trial aimed at fragile X syndrome. Founded in 2004 and based in Vancouver, Canada, the company adopted its current name in November 2024, having previously been known as Nova Mentis Life Science Corp.